Biogen Idec (BIIB) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Biogen Idec rose $6.39 (3.1%) to $215.20 on heavy volume. Throughout the day, 2,830,029 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,505,000 shares. The stock ranged in a price between $215.13-$224.63 after having opened the day at $221.68 as compared to the previous trading day's close of $208.81. Other companies within the Drugs industry that increased today were: Halozyme Therapeutics (HALO), up 24.8%, Enzon Pharmaceuticals (ENZN), up 15.6%, Ventrus Biosciences (VTUS), up 14.8% and StemCells (STEM), up 14.6%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Biogen Idec Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about BIIB
Latest from TheStreet Wire
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV